Janus Henderson Group
CBAY

Janus Henderson Group’s Cymabay Therapeutics CBAY Stock Holding History

Janus Henderson Group’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-6,103,797
Closed -$144M – 2592
2023
Q4 		$144M Sell
6,103,797
-699,687
-10% -$12.5M 0.09% 214
2023
Q3 		$101M Sell
6,803,484
-943,103
-12% -$12.5M 0.07% 243
2023
Q2 		$84.8M Buy
7,746,587
+250,538
+3% +$2.33M 0.05% 283
2023
Q1 		$65.4M Buy
7,496,049
+6,252,380
+503% +$50.1M 0.04% 323
2022
Q4 		$7.79M Buy
+1,243,669
New +$4.73M 0.01% 773

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Janus Henderson Group's CBAY Position: Q1 2024 in Review

Janus Henderson Group sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 6,103,797 shares — an estimated $144M sold.

Janus Henderson Group first reported a position in CBAY in Q4 2022 and held it in 5 quarters. The position peaked at $144M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • Janus Henderson Group reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Janus Henderson Group sold 6,103,797 Cymabay Therapeutics shares in Q1 2024, an estimated $144M.
  • Janus Henderson Group first reported a position in Cymabay Therapeutics in Q4 2022 and held it in 5 quarters.
  • Janus Henderson Group's Cymabay Therapeutics position peaked at $144M in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Janus Henderson Group's 13F filing for Q1 2024, filed 15 May 2024.